Journals / Tüberküloz ve Toraks / 2000 / Cilt: 48 - Sayı: 1

Idiopathic pulmonary fibrosis (With 12 cases)

İdiopatik pulmoner fibrozis (12 olgu nedeni ile)

Pages
57–62
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results were discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Twelve cases of idiopathic pulmonary fibrosis who had been hospitalized in our chest department evaluated for diagnostic and therapeutic management, retrospectively.
📊
Key Findings & Data:Mean age was 61.4 ± 14.3 and male/female ratio was equal.
💡
Conclusion & Impact:Results were discussed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Twelve cases of idiopathic pulmonary fibrosis who had been hospitalized in our chest department evaluated for diagnostic and therapeutic management, retrospectively. Mean age was 61.4 ± 14.3 and male/female ratio was equal. Reticular pattern was observed on %41.7 of cases, reticulonodular pattern was observed on %16.6 of cases and honey-combing presented on %41.7 of cases on high-resolution computed tomography. Pulmonary function tests showed reticular pattern. While DLCO was %59.1 ± 32.9 (mean % predictive level), mean P (A-a) O2 was found as 36.2 ± 18.3. Open lung biopsy was used for one patient as a diagnostic approach, transbronchial biopsy was chosen for 5 patients. EBV IgG was found positive on 3 cases, four patients had positive results for CMV IgG, and two patients had positive results for CMV IgM, steroids were the first choise for treatment of %58.4 of the cases. Symptomatic therapy was used for three cases (%25), clinical course wasn't observed on eight of patients (%66.7). Three patients died (%25.6). Results were discussed.

Özet

Kliniğimizde izlenen 12 İPF (İdiopatik Pulmoner Fibrozis) olgusu tanı ve tedavi yaklaşımı açısından retrospektif olarak değerlendirildi. Olguların yaş ortalaması 61.4 ± 14.3 ve erkek/kadın oranı bir idi. Yüksek rezolüsyonlu bilgisayarlı tomografi (YRBT) bulguları; 5 olguda (%41.7) interlobüler septal kalınlaşma; 2 olguda (%16.6) retikülonodüler patern, 5 olguda (%41.7) bal peteği paterni gözlendi. Solunum fonksiyon testlerinde restriktif patern gözlenirken, ortalama DLCO (% beklenen değer) %59.1 ± 32.9, alveolo-arteriyoler gradient ortalama 36.2 ± 18.3 bulundu. Tanı amaçlı bir olguya açık akciğer biyopsisi uygulanırken, 5 olguya TBAB uygulanmıştı. Üç hastada (%25) EBV IqG (+), 4 hastada (%33.3) CMV IgG (+), 2 hastada (%16.6) CMV IgM (+) bulundu. Tedavide steroidler ilk sırada yer alırken (%58.4), semptomatik tedavi (%25) ikinci sıradaydı. Serimizde yer alan 8 hastanın (%66.7) klinik seyrinin izlenemediği, 3 hastanın (%25.6) öldüğü gözlendi. Bulgular literatür bilgileri ile karşılaştırıldı.

🔖

Cite This Article

KAYA, A., KARACAN, Ö., NUMANOĞLU, N., İDİLMAN, R., SAVAŞ, İ., ARBAK, P. (2022). Idiopathic pulmonary fibrosis (With 12 cases). Tüberküloz ve Toraks, Cilt: 48 - Sayı: 1, 57–62. https://ajindex.com/articles/619459

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Talmadge EK. Diagnostic Advances in Idiopathic Pulmonary Fibrosis, Chest 1991; 100: 238-41
  2. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the Treatment of Idiopathic Pulmonary Fibrosis. Chest 1996; 110: 1058-67
  3. Reynolds HY. Diagnostic and management Strategies for Dissuse Interstitial Lung disease. Chest 1998; 113: 192-202
  4. Egan JJ, Woodcock AA, Stewart JP. Viruses and Idiopathic. Pulmonary Fibrosis, Eur Respir J 1997; 10: 1433-7
  5. Warwick MT. Interstitial Lung Disease of Unknown Etiology, Chest 1991; 100:232-3
  6. Mathieson JR, Mayo JR, Staples CA, et al. Chronic diffuse infiltrative lung disease: Comparison of diagnostic accuracy of CT and chest radiography Radiology 1983; 171: 111-6
  7. Line BR, Fulmer JD, Reynolds HY, et at. Gallium 67 citrate scanning in the staging of idiopathic pulmonary fibrosis: correlation with physiologic and morphologic features and brochoalveolar lavage,Am Rev Respir Dis 1978;118:355-65 8. Keogh BA, Crystal RG. Clinical significance of pulmonary function tests: Pulmonary function testing in interstitial pulmonary disease-what does it tell us? Chest 1980; 78: 856-65
  8. Watters LC, King TE, Schwarz Ml, et al. A clinical, radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133: 97-103
  9. Karabıyıkoğlu G, Enacar N, Bartu S. Interstisyel Akciğer Fibrozisli vakalarımızdaki pulmoner Hipertansiyon Oranı; Tüberküloz ve Toraks 1986;34:81-7
  10. Johnston IDA, Gomn SA, Kalra S, et al. The management of cryptogenic Fibrosin alveolitis in three regions of the United Kingdom. Eur Respir J 1983; 6:891-3
  11. Veda T, Ohta K, Suzuki N, et al. Idiopathic pulmonary Fibrosis and high prevalence of serum antibodies to Hepatitits C Virüs. Am Rev Respir Dis 1992; 146:266-8
  12. Vergnon JM, Vincent M, De The G, et al. Crytogenic Fibrosing alveolitis and Epstein Barr virüs: an association Lancet 1984; 768-70
  13. Kuwano K, Nomuto Y, Kunitake R, et al. Defection of adenovirus EIA DNA in pulmonary fibrosis using nested polymerase chain reaction. Eur Respir J 1997; 10: 1445-9
  14. Lunch JP, McCune WJ. Immunosupressive and cytotoxic pharmacology for pulmonary disorders. Am J Respir Crit Care Med 1997; 155:395-420
  15. Douglas WW, Rya JH, Bjoraken JA, et al. Colchicine Therapy for idiopathic pulmonary fibrosis (abstract) Am Rev Respir Crit Care Med 1996; 153: 149.